Authors

• Viknesh Selvarajah (ORCID: https://orcid.org/0000-0003-3473-4005)
• Kaisa Mäki-Petäjä (ORCID: https://orcid.org/0000-0001-7312-6200)
• Hiddo J.L. Heerspink (ORCID: https://orcid.org/0000-0002-3126-3730)
• Roberto Pecoits‐Filho (ORCID: https://orcid.org/0000-0002-0255-6710)
• Stefano Bartesaghi (ORCID: https://orcid.org/0000-0002-2083-7807)
• Alexis Hofherr (ORCID: https://orcid.org/0000-0003-2842-6161)
• Daniel Grice
• Eulalia Jiménez (ORCID: https://orcid.org/0009-0006-4351-8063)

Institutions

• University Medical Center Groningen (NL)
• University of Groningen (NL)
• Pontifícia Universidade Católica do Paraná (BR)
• AstraZeneca (South Korea) (KR)
• AstraZeneca (Australia) (AU)
• The George Institute for Global Health (AU)
• AstraZeneca (Brazil) (BR)
• AstraZeneca (Poland) (PL)
• Arbor Research Collaborative for Health (US)
• AstraZeneca (Sweden) (SE)
• AstraZeneca (Spain) (ES)

Publication Details

Journal

Journal of the American Society of Nephrology

Published

2025-12-05

DOI

https://doi.org/10.1681/asn.0000000966

Primary Topic

IL-33, ST2, and ILC Pathways

Type

article

Field-Weighted Citation Impact

0.00